A039200 Stock Overview
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Oscotec Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩24,350.00 |
| 52 Week High | ₩45,850.00 |
| 52 Week Low | ₩18,000.00 |
| Beta | 1.19 |
| 11 Month Change | -39.28% |
| 3 Month Change | -41.25% |
| 1 Year Change | 23.23% |
| 33 Year Change | -18.70% |
| 5 Year Change | 5.41% |
| Change since IPO | 225.75% |
Recent News & Updates
Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?
Aug 07
Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?
Apr 26Recent updates
Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?
Aug 07Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?
Apr 26Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?
Feb 23If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% Returns
Jan 19
Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?
Dec 15Shareholder Returns
| A039200 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -5.1% | -8.8% | -6.0% |
| 1Y | 23.2% | 9.9% | -4.4% |
Return vs Industry: A039200 exceeded the KR Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: A039200 exceeded the KR Market which returned -4.4% over the past year.
Price Volatility
| A039200 volatility | |
|---|---|
| A039200 Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A039200's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A039200's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 54 | James Kim | oscotec.com |
Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in Phase 1a/1b clinical trials for the treatment of Alzheimer’s disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide.
Oscotec Inc. Fundamentals Summary
| A039200 fundamental statistics | |
|---|---|
| Market cap | ₩916.74b |
| Earnings (TTM) | -₩26.31b |
| Revenue (TTM) | ₩4.62b |
202.7x
P/S Ratio-35.6x
P/E RatioIs A039200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A039200 income statement (TTM) | |
|---|---|
| Revenue | ₩4.62b |
| Cost of Revenue | ₩2.24b |
| Gross Profit | ₩2.38b |
| Other Expenses | ₩28.68b |
| Earnings | -₩26.31b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -684.36 |
| Gross Margin | 51.48% |
| Net Profit Margin | -569.65% |
| Debt/Equity Ratio | 36.5% |
How did A039200 perform over the long term?
See historical performance and comparison